SAB Biotherapeutics Files 8-K on Shareholder Vote Matters

Ticker: SABSW · Form: 8-K · Filed: Jul 17, 2025 · CIK: 1833214

Sab Biotherapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanySab Biotherapeutics, Inc. (SABSW)
Form Type8-K
Filed DateJul 17, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: shareholder-vote, corporate-governance, filing

TL;DR

SAB Biotherapeutics is holding a shareholder vote on July 17, 2025.

AI Summary

On July 17, 2025, SAB Biotherapeutics, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The company, formerly known as Big Cypress Acquisition Corp. until November 20, 2020, is incorporated in Delaware and headquartered in Miami Beach, Florida.

Why It Matters

This filing indicates that important decisions requiring shareholder approval are being made, which could impact the company's future direction and stock value.

Risk Assessment

Risk Level: low — The filing is a routine procedural update regarding a shareholder vote and does not disclose any immediate financial distress or significant operational changes.

Key Numbers

  • 001-39871 — SEC File Number (Identifies the company's filing history with the SEC.)
  • 85-3899721 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

  • SAB Biotherapeutics, Inc. (company) — Registrant
  • Big Cypress Acquisition Corp. (company) — Former company name
  • July 17, 2025 (date) — Date of report and earliest event
  • November 20, 2020 (date) — Date of former company name change
  • Miami Beach, Florida (location) — Principal executive offices

FAQ

What specific matters are being submitted for a vote by SAB Biotherapeutics' security holders?

The filing states it is a 'Submission of Matters to a Vote of Security Holders' but does not detail the specific proposals in the provided text.

When was SAB Biotherapeutics, Inc. formerly known as Big Cypress Acquisition Corp.?

The company changed its name from Big Cypress Acquisition Corp. on November 20, 2020.

Where are SAB Biotherapeutics, Inc.'s principal executive offices located?

The principal executive offices are located at 777 W 41st St Suite 401, Miami Beach, Florida, 33140.

What is the SEC file number for SAB Biotherapeutics, Inc.?

The SEC file number for SAB Biotherapeutics, Inc. is 001-39871.

On what date was this 8-K report filed?

This 8-K report was filed on July 17, 2025.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on July 17, 2025 regarding SAB Biotherapeutics, Inc. (SABSW).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.